Sisili specialised Medical Services Opens First Ever EECP Treatment Centre in Colombo
Sisili, a leader in the medical field has now launched the HeartAid Centre, the first non-invasive treatment and outpatient management of cardiovascular diseases under the auspicious of Hon. Minister of Health, Nutrition and Indigenous Medicine, Dr. Rajitha Senaratne. With the opening of the HeartAid Centre, it allows Sri Lankans to now have access to the newest enhanced external counter pulsation therapy system.
The Hon. Minister stated “Noncommunicable diseases are increasingly becoming a burden to Sri Lanka and is now among the top priorities of the Ministry of Health. Nearly 65% of the hospital deaths in Sri Lanka are due to major non-communicable diseases such as heart disease, stroke, diabetes and chronic respiratory diseases. Heart conditions are considered medical emergencies and need prompt attention by specialists, and with the introduction of such modern non- invasive treatment by the private sector, patients have access to treatment opportunities locally. Today, we see the addition of a yet another specialized treatment unit. The Ministry of Health welcomes this move as this will further enhance the national capacity in delivering a quality health service to our people.”
Dr. Gotabhaya Ranasinghe, Consultant Cardiologist at the National Hospital of Sri Lanka, who was also a distinguished invitee at the launch stated that, “This is a long awaited treatment option for patients who don’t get maximum benefit from optimum anti-anginal treatment and who are not suitable for a surgical option.”
The EECP Therapy System is a non-invasive external counter pulsation device for the treatment of patients suffering from chronic stable angina that is refractory to optimal anti- anginal medical therapy without options for revascularization. It is the latest line of devices for the treatment of patients with advanced heart disease, including angina and heart failure.
Data from clinical studies and patient registries confirm that approximately 80 percent of patients who complete EECP therapy experience significant relief from chronic coronary artery disease ( CAD) symptoms, including reduction or elimination of angina, reduced need for medication, increased functional capacity and improved quality of life. Published data show that the benefit of EECP therapy is durable and can persist for up to five years. For patients who are good candidates for the treatment, EECP therapy is considered a high benefit and low cost option.